InvestmentMay 4, 2026, 08:19 AM
Reliance Global Group's LifeSci Global Invests $2M in Innervate
AI Summary
Reliance Global Group's biotech division, LifeSci Global, completed a strategic investment of $2.0 million in Innervate Radiopharmaceuticals, a developer of PET imaging and therapeutic radiopharmaceuticals. This investment, with an initial funding of $500,000, expands EZRA International Group's biotech division into late-stage radiopharmaceutical imaging, initially targeting neuroblastoma with an estimated $250 million market opportunity. The transaction also offers potential expansion into cardiovascular and neurodegenerative diseases, each with over $1 billion market potential, and the upside of a Priority Review Voucher.
Key Highlights
- LifeSci Global, Reliance's biotech arm, invested $2.0 million in Innervate Radiopharmaceuticals.
- LifeSci Global acquired 421,053 shares of Innervate at $4.75 per share.
- Initial funding of $500,000 was provided at closing.
- Innervate's lead asset, 18F-mFBG, targets neuroblastoma, an estimated $250 million market.
- Future applications in cardiovascular and neurodegenerative diseases could each exceed $1 billion.
- The investment provides potential for a valuable Priority Review Voucher.
- PET imaging and radiopharmaceuticals market has annual U.S. sales over $2 billion and global sales over $5 billion.